-
Something wrong with this record ?
Decitabine and SAHA-induced apoptosis is accompanied by survivin downregulation and potentiated by ATRA in p53-deficient cells
B. Brodská, P. Otevřelová, A. Holoubek,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 2008
PubMed Central
from 2008
Europe PubMed Central
from 2008
ProQuest Central
from 2014-01-01
Open Access Digital Library
from 2008-01-01
Open Access Digital Library
from 2008-01-01
Open Access Digital Library
from 2009-01-01
Medline Complete (EBSCOhost)
from 2011-01-01
Health & Medicine (ProQuest)
from 2014-01-01
Wiley-Blackwell Open Access Titles
from 2008
PubMed
25140197
DOI
10.1155/2014/165303
Knihovny.cz E-resources
- MeSH
- Apoptosis drug effects MeSH
- Azacitidine analogs & derivatives toxicity MeSH
- Down-Regulation drug effects MeSH
- HL-60 Cells MeSH
- Inhibitor of Apoptosis Proteins metabolism MeSH
- G2 Phase Cell Cycle Checkpoints drug effects MeSH
- M Phase Cell Cycle Checkpoints drug effects MeSH
- Hydroxamic Acids toxicity MeSH
- Humans MeSH
- Lymphocytes cytology drug effects immunology MeSH
- Cell Line, Tumor MeSH
- Tumor Suppressor Protein p53 deficiency genetics MeSH
- Antimetabolites, Antineoplastic pharmacology MeSH
- Reactive Oxygen Species metabolism MeSH
- Drug Synergism MeSH
- Tretinoin pharmacology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
While p53-dependent apoptosis is triggered by combination of methyltransferase inhibitor decitabine (DAC) and histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in leukemic cell line CML-T1, reactive oxygen species (ROS) generation as well as survivin and Bcl-2 deregulation participated in DAC + SAHA-induced apoptosis in p53-deficient HL-60 cell line. Moreover, decrease of survivin expression level is accompanied by its delocalization from centromere-related position in mitotic cells suggesting that both antiapoptotic and cell cycle regulation roles of survivin are affected by DAC + SAHA action. Addition of subtoxic concentration of all-trans-retinoic acid (ATRA) increases the efficiency of DAC + SAHA combination on viability, apoptosis induction, and ROS generation in HL-60 cells but has no effect in CML-T1 cell line. Peripheral blood lymphocytes from healthy donors showed no damage induced by DAC + SAHA + ATRA combination. Therefore, combination of ATRA with DAC and SAHA represents promising tool for therapy of leukemic disease with nonfunctional p53 signalization.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15014093
- 003
- CZ-PrNML
- 005
- 20150428115219.0
- 007
- ta
- 008
- 150420s2014 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1155/2014/165303 $2 doi
- 035 __
- $a (PubMed)25140197
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Brodská, Barbora $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.
- 245 10
- $a Decitabine and SAHA-induced apoptosis is accompanied by survivin downregulation and potentiated by ATRA in p53-deficient cells / $c B. Brodská, P. Otevřelová, A. Holoubek,
- 520 9_
- $a While p53-dependent apoptosis is triggered by combination of methyltransferase inhibitor decitabine (DAC) and histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in leukemic cell line CML-T1, reactive oxygen species (ROS) generation as well as survivin and Bcl-2 deregulation participated in DAC + SAHA-induced apoptosis in p53-deficient HL-60 cell line. Moreover, decrease of survivin expression level is accompanied by its delocalization from centromere-related position in mitotic cells suggesting that both antiapoptotic and cell cycle regulation roles of survivin are affected by DAC + SAHA action. Addition of subtoxic concentration of all-trans-retinoic acid (ATRA) increases the efficiency of DAC + SAHA combination on viability, apoptosis induction, and ROS generation in HL-60 cells but has no effect in CML-T1 cell line. Peripheral blood lymphocytes from healthy donors showed no damage induced by DAC + SAHA + ATRA combination. Therefore, combination of ATRA with DAC and SAHA represents promising tool for therapy of leukemic disease with nonfunctional p53 signalization.
- 650 _2
- $a protinádorové antimetabolity $x farmakologie $7 D000964
- 650 _2
- $a apoptóza $x účinky léků $7 D017209
- 650 _2
- $a azacytidin $x analogy a deriváty $x toxicita $7 D001374
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a down regulace $x účinky léků $7 D015536
- 650 _2
- $a synergismus léků $7 D004357
- 650 _2
- $a kontrolní body fáze G2 buněčného cyklu $x účinky léků $7 D059565
- 650 _2
- $a HL-60 buňky $7 D018922
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kyseliny hydroxamové $x toxicita $7 D006877
- 650 _2
- $a inhibitory apoptózy $x metabolismus $7 D051034
- 650 _2
- $a lymfocyty $x cytologie $x účinky léků $x imunologie $7 D008214
- 650 _2
- $a kontrolní body M fáze buněčného cyklu $x účinky léků $7 D059566
- 650 _2
- $a reaktivní formy kyslíku $x metabolismus $7 D017382
- 650 _2
- $a tretinoin $x farmakologie $7 D014212
- 650 _2
- $a nádorový supresorový protein p53 $x nedostatek $x genetika $7 D016159
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Otevřelová, Petra $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.
- 700 1_
- $a Holoubek, Aleš $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.
- 773 0_
- $w MED00180520 $t Oxidative medicine and cellular longevity $x 1942-0994 $g Roč. 2014, č. - (2014), s. 165303
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25140197 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150420 $b ABA008
- 991 __
- $a 20150428115522 $b ABA008
- 999 __
- $a ok $b bmc $g 1071674 $s 896971
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 2014 $c - $d 165303 $i 1942-0994 $m Oxidative medicine and cellular longevity $n Oxid Med Cell Longev $x MED00180520
- LZP __
- $a Pubmed-20150420